Dr Reddy's Laboratories has received approval from Health Canada to sell a generic version of the diabetes drug semaglutide, making it the first company to get market authorisation for a generic semaglutide injection in Canada and the first in a G7 country.
The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.
The 30-share Sensex ended higher by 31 points at 26,591 and the 50-share Nifty gained 10 points at 8,061.
